TARA - Long Setup Possible entry above 7.32, Stop signal 5.93., First target 8.37, 2nd target momentum. Strong insider buying
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.82 USD
−40.42 M USD
0.00 USD
30.63 M
About Protara Therapeutics, Inc.
Sector
CEO
Jesse Shefferman
Headquarters
New York
Website
Founded
2006
FIGI
BBG001ZLYSH5
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.
$TARA lets go whale hunting*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Early this
Protara Therapeutics Inc 🧙Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatmen
TARA Technical Analysis 🧙Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatmen
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of TARA is 5.39 USD — it has increased by 4.05% in the past 24 hours. Watch Protara Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Protara Therapeutics, Inc. stocks are traded under the ticker TARA.
TARA stock has fallen by −15.52% compared to the previous week, the month change is a 134.35% rise, over the last year Protara Therapeutics, Inc. has showed a 199.44% increase.
We've gathered analysts' opinions on Protara Therapeutics, Inc. future price: according to them, TARA price has a max estimate of 50.00 USD and a min estimate of 14.00 USD. Watch TARA chart and read a more detailed Protara Therapeutics, Inc. stock forecast: see what analysts think of Protara Therapeutics, Inc. and suggest that you do with its stocks.
TARA reached its all-time high on Jul 17, 2015 with the price of 800.00 USD, and its all-time low was 1.04 USD and was reached on Nov 22, 2023. View more price dynamics on TARA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
TARA stock is 7.98% volatile and has beta coefficient of 2.23. Track Protara Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Protara Therapeutics, Inc. there?
Today Protara Therapeutics, Inc. has the market capitalization of 184.98 M, it has decreased by −10.08% over the last week.
Yes, you can track Protara Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Protara Therapeutics, Inc. is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
TARA earnings for the last quarter are −0.50 USD per share, whereas the estimation was −0.52 USD resulting in a 3.85% surprise. The estimated earnings for the next quarter are −0.51 USD per share. See more details about Protara Therapeutics, Inc. earnings.
Protara Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
TARA net income for the last quarter is −11.22 M USD, while the quarter before that showed −9.51 M USD of net income which accounts for −17.93% change. Track more Protara Therapeutics, Inc. financial stats to get the full picture.
No, TARA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 27.00 employees. See our rating of the largest employees — is Protara Therapeutics, Inc. on this list?
Like other stocks, TARA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Protara Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Protara Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Protara Therapeutics, Inc. stock shows the buy signal. See more of Protara Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.